2015, Número 2
Siguiente >>
Med Sur 2015; 22 (2)
Aspectos generales del trasplante hepático
Visag-Castillo V, Díaz-Girón-Gidi A, Vélez-Pérez F, Castro-Narro G, Contreras-Saldívar A
Idioma: Español
Referencias bibliográficas: 43
Paginas: 49-56
Archivo PDF: 149.64 Kb.
RESUMEN
Introducción. En la actualidad el trasplante hepático (TH) es
considerado como el tratamiento de elección para hepatopatías
terminales agudas y crónicas.
Objetivo. Revisar el estado actual
del TH e identificar directrices para futuras investigaciones clínicas.
Material y métodos. Miembros del subcomité de TH revisaron e
interpretaron la literatura para describir generalidades del estado
actual del TH.
Resultados. Las indicaciones para TH son diversas
con excelentes resultados a corto y largo plazo en centros de alto
volumen. Es necesario realizar un escrutinio adecuado al momento
de elegir al receptor mediante un equipo multidisciplinario, ya que
al ser un procedimiento de alta especialidad y complejidad técnica,
puede presentar complicaciones que pueden ser manejadas
adecuadamente por los miembros del equipo.
Conclusiones. El
TH es la mejor opción terapéutica para el tratamiento definitivo de
hepatopatías terminales e insuficiencia hepática; es tarea de los
especialistas difundir información relacionada con donación de
órganos y trasplantes.
REFERENCIAS (EN ESTE ARTÍCULO)
Starzl TE, Groth CG, Brettschneider L. Etal Orthotopic homotrasplantations of the human liver. Ann Surg 1968; 168: 392-414.
O’Learly JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134: 1764-76.
Weisner R, Edwards E, Freeman R, et al. MELD and allocation of donor livers. Gastroenterology 2003; 124(1): 91-6.
Merion M, Shaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transpl 2005; 5: 307-13.
Bernal W, Hyyryleinen A, Gera A, et al. Lessons from look back in acute liver failure? A single center experience of 3,300 patients. J Hepatol 2013; 59: 74-80.
Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-72.
Dhiman R, Jain S, Maheswari U, et al. Early indicators of prognosis in fulminant hepatic failure: an assesment of the MELD and King’s College hospital criteria. Liver Transpl 2007; 13: 814-21.
Berenguer M, Wright TL. Treatment strategies for recurrent hepatitis C after liver transplantation. Clin Liver Dis 1999; 3: 883-99.
Gane E. Pre- and post-transplant treatment of hepatitis C. J Gastroenterol Hepatol 2000; 6: S35-S40.
Price JC, Terrault NA. Treatment of hepatitis c in liver transplant patients: interferon out, direct antiviral combos in. Liver Transpl 2015; 21: 423-34.
Neuberger J, Schulz KH, Day C, Fleig W, Berlakovich GA, Berenguer M, Pageaux GP, et al. Transplantation for alcoholic liver disease. J Hepatol 2002; 36(1): 130-7.
Howard LM, Williams R, Fahy TA. The psychiatric assessment of liver transplant patients with alcoholic liver disease: a review. J Psychosom Res 1994; 38: 643-53.
Younossi ZM. Review article: Current management of non-alcoholic fatty liver disease and non alcoholic steatohepatitis. Aliment Pharmacol Ther 2008; 28: 2-12.
Lierman Garcia RF, Evangelista Garcia C, McMaster P, et al. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology 2001; 33: 22-7.
Gow PJ, Chapman RW. Liver transplantation for primary sclerosing colangitis. Liver 2000; 20: 97-103.
Faust TW. Recurrent primary biliary cirrosis, primary sclerosing colangitis and autoinmune hepatitis after trasnplantation. Liver Transpl 2001; 7: S99-S108.
Hemming AW, Nelson DR, Reed AI. Liver transplantation for hepatocellular carcinoma. Minerva Chir 2002; 57: 575-85.
Mazzferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med 1996; 334: 693-9.
Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991; 214(3): 221-8.
Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246(3): 502-9.
De Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6(12): 2983-93.
Martinez-Palli G, Taura P, Balust J, et al. Liver transplantation in high risk patients: Hepatopulomonary syndrome and portopulmonary hypertension. Transplant Proc 2005; 37: 3861-4.
Dew MA, DiMartini AF, De Vito, Dabbs A, et al. Rates and risks factors for non adherence to the medical regimen after adult solid organ transplantation. Transplantation 2007; 83: 858-73.
Kamath PS, Weisner RH, Malinochoc M, et al. A model to predict survival in patients wit end-stage liver disease. Hepatology 2001; 33: 464-70.
Martin AP, Bartels M, Hauss J, et al. Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007; 39: 3169-74.
Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefitbased deceased-donor liver allocation. Am J Transplant 2009; 9: 970-81.
Starzl TE, Todo S, et al. Transplantation of multiple abdominal viscera. JAMA 1989; 261: 1449-57.
Ghobrial RM, Amersi F, Busuttil RW. Surgical advances in liver transplantation. Living related and Split donors. Clin Liver Dis 2000; 4: 553-65.
Nishida S, Nakamura N, Vaidya A, Levi DM, Kato T, et al. Piggyback technique in adult orthotopic liver transplantation: an analysis of 1067 liver transplants at a single center. HPB 2006; 8(3): 182-8.
Jaramillo-Gante MA, Vilatobá-Chapa M. Complicaciones posquirúrgicas en trasplante de hígado. En: López-Méndez. Conceptos de diagnóstico y tratamiento en hepatología y gastroenterología. México: Fundación Mexicana para la Salud; 2012, p. 167-76.
Duffy JP, Hong JC, Farmer DG, Ghobrial RM, Yersiz H, Hiatt JR, Busuttil RW. Vascular complications of orthotopic liver transplantation: experience in more tan 4,200 patients. J Am Coll Surg 2009; 208(5): 863-903.
Reid S, Scoutt L, Hamper U. Vascular complications of liver transplants: Evaluation with duplex Doppler ultrasound. Ultrasound Clin 2011; 6: 513-30.
Quiroga S, Sebastia MC, Margarit C, Castells LL, Boyé R, Alvarez- Castells A. Complications of Orthotopic Liver Transplantation: Spectrum of Findings with Helical CT. RadioGraphics 2001; 21: 1085-102.
Koo BY, Yu HC, So MC, Jin GY, Kwak HS, Cho BH. Endovascular management of early portal vein thrombosis caused by coronary vein steal after liver transplantation and its outcome. Clin Transplant 2008. Doi: 10.1111/j.1399-0012.2008.00822.x.
Pareja E, Cortes M, Navarro R, Sanjuan F, Lopez R, Mir J. Vascular complications after orthotopic liver transplantation: hepatic artery thrombosis. Transplant Proc 2010; 42(8): 2970-2.
Jung SW, Hwang S, Namgoong JM, Yoon SY, et al. Incidence and management of postoperative abdominal bleeding after liver transplantation. Transplant Proc 2012; 44(3): 765-8.
Seehofer D, Eurich A, Veltzke-Schlieker A, Neuhaus P. Biliary complications after liver transplantation: Old problems and new challenges. Am J Transpl 2013; 13: 253-65.
Pillai AA, Levitsky J. Overview of immunosuppression in liver transplantation. World J Gastroenterol 2009; 15: 4225-33.
Sollinger HW. Mycophenolates in transplantation. Clin Transplant 2004; 18: 485-92.
Sgourakis G, Radtke A, Fouzas I, et al. Corticosteroid-free immunosuppression in liver transplantation: A meta-analysis and metaregression of outcomes. Transpl Int 2009; 22: 892-905.
Watson CJ, Friend PJ, Jamieson NV, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67: 505-9.
Disponible en: http://www.cenatra.salud.gob.mx/
Salvaggio PR, Caicedo JC, Carneiro de AL, Contreras A, Vilatoba M, et al. Liver transplantation in Latin America: The State-of-the-Art and future trends. Trasplantation 2014; 98: 241-6.